XWELL, Inc. Reports Second Quarter 2024 Results

Rhea-AI Summary

XWELL, Inc. (Nasdaq: XWEL) reported Q2 2024 results with notable highlights:

- Revenue growth of 14% year-over-year to $9.3 million
- Opened new XpresSpa in Philadelphia International Airport
- Introduced IV-hydration therapy and Ceragem massage beds in select locations
- Reduced operating expenses by 16% compared to Q2 2023
- Executed a $1.4 million registered direct offering
- Expanded Naples Wax Center services and plans for growth
- Anticipates new CDC biosurveillance contract in Q3 2024

Financial results:
- Operating loss: $1.9 million (improved from $4.7 million in Q2 2023)
- Net loss: $2.0 million (improved from $5.7 million in Q2 2023)
- Cash and cash equivalents: $5.4 million
- Marketable securities: $13.0 million

Positive

• Revenue growth of 14% year-over-year to $9.3 million
• Reduced operating expenses by 16% compared to Q2 2023
• Improved operating loss to $1.9 million from $4.7 million in Q2 2023
• Improved net loss to $2.0 million from $5.7 million in Q2 2023
• Executed a $1.4 million registered direct offering priced at a premium to market
• Opened new XpresSpa location in Philadelphia International Airport
• Introduced new services like IV-hydration therapy and Ceragem massage beds
• Expanded Naples Wax Center services and plans for growth to 10 locations by early 2025
• Anticipates new CDC biosurveillance contract in Q3 2024 with similar value to prior contracts

Negative

• Still operating at a loss of $1.9 million for the quarter
• Net loss of $2.0 million for the quarter

Financial Analyst

XWELL's Q2 2024 results show mixed signals. On the positive side, revenue grew by 14% year-over-year, driven by increased demand for services and retail products. The company has also made significant progress in reducing costs, with operating expenses down by 16% compared to Q2 2023. However, XWELL is still operating at a loss, albeit smaller than the previous year.

The company's liquidity position appears stable with $5.4 million in cash and $13 million in marketable securities. The recent $1.4 million direct offering, priced at a premium to market, provides additional working capital. While this demonstrates investor confidence, it also indicates a need for additional funding.

XWELL's strategy to diversify beyond airports, exemplified by the Naples Wax Center acquisition and the upcoming Penn Station location, could provide new growth avenues. The potential renewal of the CDC biosurveillance contract could also provide a stable revenue stream. However, the company needs to accelerate its path to profitability to ensure long-term sustainability.

Market Research Analyst

XWELL's expansion strategy aligns with current wellness trends. The introduction of IV hydration therapy and innovative massage solutions in airports caters to the growing demand for quick, convenient wellness services among travelers. The company's move into non-airport locations, such as Penn Station and the Naples Wax Center expansion, demonstrates an understanding of the broader wellness market potential.

The labor-lite, tech-forward approach in new locations is particularly noteworthy. This model could help XWELL improve profitability by reducing labor costs while still meeting consumer demands. The integration of services like Ceragem massage beds and Clockwork MiNiCURE shows adaptability to automation trends in the wellness industry.

However, XWELL faces challenges in a competitive wellness market. The success of its expansion plans will depend on effective differentiation and maintaining service quality across diverse locations. The company's ability to leverage its airport experience in other high-traffic areas will be important for future growth and profitability.

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the second quarter ended June 30, 2024.

Recent Highlights:

• XWELL delivered 2024 second quarter revenue growth of approximately 14% from the comparable quarter in 2023 driven by stronger demand for services and retail products.
• In June, XpresSpa opened a new spa in Philadelphia International Airport -- its first in a U.S. airport in more than 5 years and the first to leverage the Company’s “labor-lite, tech-forward” offering.
• In June, the CDC issued a new three-year biosurveillance program RFP which XpresTest is answering and, if awarded, will commence during the third quarter of 2024. It is anticipated that the value of this new contract will be similar to prior contracts.
• In May, Naples Wax began offering aesthetic services as part of its evolution as a full-service spa.
• In May, XpresSpa launched a program to introduce IV-hydration therapy into its spa locations.
• XWELL continues to focus on reducing its cost structure and returning to profitability including:
  • Reducing cost of sales by approximately 11% when compared to the 2023 second quarter.
  • Reducing general and administrative expenses by approximately 3% when compared to the 2023 second quarter.
  • Reducing salaries and benefits by approximately 22% when compared to the 2023 second quarter.
  • Reducing operating expenses by approximately 16% when compared to the 2023 second quarter.
• In August, XWELL continued to fuel its future growth plans by executing a $1.4 million registered direct offering, which was priced at a premium to market.
  

“We continue to look towards the future, successfully implementing our strategy to balance our portfolio with growth outside the airport, and cost-effectively integrating innovative services and retail products into our offering,” commented Scott Milford, XWELL’s Chief Executive Officer. “At the same time, we remain laser-focused on returning to profitability and are pleased with the significant progress we’ve made reducing costs and operating expenses. Looking ahead, we remain focused on continuous improvement across our business, and we believe we’re well positioned to extend our collaboration with the CDC for our traveler-based SARS-CoV-2 Genomic Surveillance program.”

Travel Wellness Portfolio - XpresSpa®
XpresSpa is the leading airport retailers of wellness services and related products, with 33 locations in 16 airports globally.

During the 2024 second quarter, XpresSpa opened a new location in Philadelphia International Airport (PHL). Located in Terminal B near Gate B2, the PHL XpresSpa includes the company’s new branding as well as innovative offerings including its new Ceragem therapeutic massage and compression beds, Clockwork MiNiCURE and Human Touch automated massages. With more than 28 million passengers annually, the Company believes the PHL XpresSpa represents an exciting opportunity to drive a sustainable and profitable model with its labor lite and tech forward offerings.

Additionally, during the 2024 second quarter, the Company announced the introduction of IV hydration drip therapy at its Miami International Airport (MIA) XpresSpa location. In collaboration with Revitalize IV Lounge, the new service offers a fast and efficient way to deliver vitamins, minerals, and amino acids directly into the bloodstream and is available in MIA’s North Terminal, Concourse D, Gate D-11. The introduction of hydration therapies in our spa locations aligns with our continued desire to offer a wider variety of “on-trend” wellness services.

Additionally, during the 2024 second quarter, XpresSpa also announced the launch of its first use of the Ceragem V-6 massage bed providing therapeutic massage to guests. The fully autonomous massage solution is designed to rejuvenate and revolutionize relaxation by providing enhanced blood circulation, muscle and joint discomfort, as well as muscle relaxation. This device combines touchless massage, compression, and heat therapy to provide users with a blissful experience of relaxation and relief. Locations for the Ceragem V-6 include Salt Lake City International Airport (SLC), Philadelphia International Airport (PHL) and Orlando International Airport (MCO).

New York City’s Penn Station XpresSpa
Consistent with XWELL’s strategy to extend its footprint into transportation hubs, the Company is opening an XpresSpa location in New York City’s Penn Station. The labor-lite, tech-forward spa will serve commuters, neighborhood locals, and tourists with wellness-focused retail, autonomous massage, and nail care services, enabling seamless and efficient experiences for time-crunched New York City travelers. The Penn Station XpresSpa is expected to open to commuters later this year.

Out-of-Airport Wellness Portfolio - Naples Wax Center®
XWELL’s first off-airport brand, Naples Wax Center, is a group of upscale hair removal and aesthetic services boutiques with current locations in Florida. Acquired in mid-September 2023, Naples Wax Center provides core products and service including face and body waxing as well as a range of skincare and cosmetic products from its current three locations.

During the 2024 second quarter, the Company announced the introduction of elevated esthetic facial services at its Naples Wax Center flagship location in Naples, FL. The new offerings include a Microderm Infusion Facial, LightStim® Invigorating Light Facial and Classic Refreshing Facial. Additionally, Naples Wax Center is introducing curated retail product lines that align with its new service offerings, including SkinMedica and PCA Skin.

The Company is intending to execute additional leases in Florida, forecasting approximately 10 Naples Wax Center locations by early 2025. XWELL also intends to extend its reach across the Southeast. As new locations are opened, they will also incorporate the additional aesthetic services into the Naples Wax Center model to drive new revenue and broaden their offering.

Life Sciences & Biosurveillance -- XpresCheck® and HyperPointe™
The Company XpresTest, Inc. subsidiary (“XpresCheck”), in collaboration with the Centers for Disease Control and Prevention (“CDC”) and Ginkgo Bioworks, currently operates 9 biosurveillance stations in 7 of the nation’s busiest airports.

As noted, in June 2024, the CDC issued a new 3-year biosurveillance program RFP which XpresTest is answering and, if awarded, will commence during the third quarter of 2024. It is anticipated that the value of this new contract will be similar to prior contracts.

XpresTest, Inc began conducting bio surveillance monitoring with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo Bioworks in 2021. The program was extended in January 2022 and renewed in August of 2022 and 2023. In March 2024, the program’s funding and scope were expanded to an estimated $36.7 million or more.

TGS is a flexible, multimodal platform that consists of four complementary approaches of sample collection from arriving international travelers at U.S. airports, including voluntary nasal swabbing, aircraft wastewater, air monitoring and airport wastewater sampling to enhance early detection of new SARS-CoV-2 variants and other pathogens, and fill gaps in global surveillance.

Additionally, the Company began reporting operating results for HyperPointe within its XpresCheck business. Beginning in June 2020, and following its acquisition by XWELL in January 2022, HyperPointe’s management team and suite of services and technology have been utilized to develop and deploy the technological infrastructure necessary to scale the growth of the XpresCheck business. HyperPointe’s experience in this space continues to play a critical role in the expansion of ongoing biosurveillance efforts created in partnership with Ginkgo Bioworks and the CDC.

HyperPointe is a leading digital healthcare and data analytics relationship marketing agency, servicing the global healthcare and pharmaceutical industry. HyperPointe has significant experience in patient and healthcare professional marketing and deep technological experience with CXM (customer experience management) and data analytics.

Liquidity and Financial Condition
As of June 30, 2024, the Company had approximately $5.4 million of cash and cash equivalents (excluding restricted cash), approximately $13.0 million in marketable securities, total current assets of approximately $23.1 million, and no long-term debt.

Direct Offering and Shareholder Engagement
Additionally, on August 8, 2024, the Company closed its registered direct offering priced at a premium to market for the issuance and sale of an aggregate of 652,705 shares of its common stock, par value $0.01 per share, at a purchase price of $2.18 per share. The gross proceeds to the Company from the offering were approximately $1.4 million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds of this offering for working capital and general corporate purposes.

Furthermore, on August 13, 2024 the Company announced the withdrawal of a previously filed lawsuit from CPC Pain & Wellness SPV, LLC (“CPC”), which concerned CPC’s invalid director candidate nomination notice. The Company appreciates the opportunity to engage with its stockholders and welcomes constructive feedback. The Company is pleased with the outcome of this dialogue and continues to focus on the strategic plan and delivering long-term value for all stockholders.

Summary Second Quarter 2024 Financial Results
Total revenue for the second quarter ended June 30, 2024, was $9.3 million compared to $8.2 million for the 2023 second quarter.

Revenue for the 2024 second quarter primarily consisted of approximately $4.9 million from XpresSpa locations and Treat locations and approximately $3.8 million from XpresTest, which includes XWELL’s biosurveillance partnership and its HyperPointe business. Naples Wax Center, which was acquired near the end of the 2023 third quarter, accounted for approximately $0.5 million.

Total Cost of Sales
Total cost of sales was approximately $6.2 million compared to approximately $7.0 million for the 2023 second quarter.

Salaries and Benefits; General and Administrative Expenses
Salaries and benefits were approximately $1.7 million compared to $2.1 million for the 2023 second quarter. General and administrative expenses were approximately $3.1 compared to approximately $3.2 million for the 2023 second quarter.

Total Operating Expenses
Total operating expenses were approximately $5.0 million compared to approximately $5.9 million for the 2023 second quarter.

Operating Loss
The operating loss was approximately $1.9 million compared with an operating loss of approximately $4.7 million for the 2023 second quarter.

Net Loss Attributable to XWELL
Net loss attributable to XWELL was approximately $2.0 million compared to approximately $5.7 million for the 2023 second quarter.

About XWELL, Inc. 

XWELL, Inc. (Nasdaq: XWEL) is a leading global wellness holding company operating multiple brands: XpresSpa®, Treat™, Naples Wax Center®, XpresCheck® and HyperPointe™.

• XpresSpa is a leading retailer of wellness services and related products, with 33 locations in 16 airports globally.
• Naples Wax Center is a group of upscale skin care boutiques, with three locations currently operating.
• XpresCheck, in partnership with the CDC and Concentric by Ginkgo, conducts biosurveillance monitoring in its airport locations to identify new variants of interest and concern as well as other pathogens entering the country from across the world.
• HyperPointe is a leading digital healthcare and data analytics relationship company serving the global healthcare industry. 

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events, including the Company’s current plans and expectations relating to the business and operations and future store openings, including but not limited to, future openings of Naples Wax Center and XpresSpa stores, are based upon information available to XWELL as of the date of this press release, and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company’s Annual Report on Form 10-K, as amended, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XWELL, or other matters and attributable to XWELL or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XWELL does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Media
Maria Kucinski
MWW 
mkucinski@mww.com

FAQ

What was XWELL's (XWEL) revenue growth in Q2 2024?

XWELL reported revenue growth of approximately 14% in Q2 2024 compared to the same quarter in 2023.

How much did XWELL (XWEL) reduce its operating expenses in Q2 2024?

XWELL reduced its operating expenses by approximately 16% in Q2 2024 compared to the second quarter of 2023.

What new services did XWELL (XWEL) introduce in its XpresSpa locations in Q2 2024?

XWELL introduced IV-hydration therapy and Ceragem therapeutic massage beds in select XpresSpa locations during Q2 2024.

How many Naples Wax Center locations does XWELL (XWEL) plan to have by early 2025?

XWELL plans to have approximately 10 Naples Wax Center locations by early 2025.

What was XWELL's (XWEL) net loss for Q2 2024?

XWELL reported a net loss of approximately $2.0 million for Q2 2024.